Lupus anticoagulant

clinical significance in anticardiolipin positive patients with systemic lupus erythematosus

N J McHugh, D A Moye, I E James, M Sampson, P J Maddison

Research output: Contribution to journalArticle

Abstract

The significance of anticardiolipin antibodies and the lupus anticoagulant was studied in 58 consecutive patients with systemic lupus erythematosus. On 85 occasions serum IgG and IgM anticardiolipin antibodies were measured by an enzyme linked immunosorbent assay (ELISA), and simultaneous plasma samples tested for lupus anticoagulant activity. The most significant association with clinical events (previous thrombosis or thrombocytopenia occurring in 11/58 patients) was with prolonged tissue thromboplastin inhibition time (TTIT) followed by prolonged kaolin cephalin clotting time (KCCT) then raised IgG anticardiolipin antibody concentrations and dilute Russell's viper venom time. Although IgG anticardiolipin antibodies or KCCT were the most sensitive tests in identifying this group, the TTIT was the most specific (98%). Nine patients were IgG anticardiolipin antibody positive and lupus anticoagulant negative, of whom one had thrombocytopenia but none had thrombosis. The presence of a lupus anticoagulant in anticardiolipin antibody positive patients increases specificity for certain adverse clinical events.
Original languageEnglish
Pages (from-to)548-52
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume50
Issue number8
Publication statusPublished - 1991

Fingerprint

Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Systemic Lupus Erythematosus
Immunoglobulin G
Phosphatidylethanolamines
Kaolin
Thromboplastin
Thrombocytopenia
Thrombosis
Viper Venoms
Immunosorbents
Prothrombin Time
Immunoglobulin M
Assays
Thermodynamic properties
Enzyme-Linked Immunosorbent Assay
Association reactions
Plasmas
Enzymes
Serum

Cite this

Lupus anticoagulant : clinical significance in anticardiolipin positive patients with systemic lupus erythematosus. / McHugh, N J; Moye, D A; James, I E; Sampson, M; Maddison, P J.

In: Annals of the Rheumatic Diseases, Vol. 50, No. 8, 1991, p. 548-52.

Research output: Contribution to journalArticle

@article{fbc0b9a386274f5982b7e6046d6c52a4,
title = "Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus",
abstract = "The significance of anticardiolipin antibodies and the lupus anticoagulant was studied in 58 consecutive patients with systemic lupus erythematosus. On 85 occasions serum IgG and IgM anticardiolipin antibodies were measured by an enzyme linked immunosorbent assay (ELISA), and simultaneous plasma samples tested for lupus anticoagulant activity. The most significant association with clinical events (previous thrombosis or thrombocytopenia occurring in 11/58 patients) was with prolonged tissue thromboplastin inhibition time (TTIT) followed by prolonged kaolin cephalin clotting time (KCCT) then raised IgG anticardiolipin antibody concentrations and dilute Russell's viper venom time. Although IgG anticardiolipin antibodies or KCCT were the most sensitive tests in identifying this group, the TTIT was the most specific (98{\%}). Nine patients were IgG anticardiolipin antibody positive and lupus anticoagulant negative, of whom one had thrombocytopenia but none had thrombosis. The presence of a lupus anticoagulant in anticardiolipin antibody positive patients increases specificity for certain adverse clinical events.",
author = "McHugh, {N J} and Moye, {D A} and James, {I E} and M Sampson and Maddison, {P J}",
year = "1991",
language = "English",
volume = "50",
pages = "548--52",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group Ltd",
number = "8",

}

TY - JOUR

T1 - Lupus anticoagulant

T2 - clinical significance in anticardiolipin positive patients with systemic lupus erythematosus

AU - McHugh, N J

AU - Moye, D A

AU - James, I E

AU - Sampson, M

AU - Maddison, P J

PY - 1991

Y1 - 1991

N2 - The significance of anticardiolipin antibodies and the lupus anticoagulant was studied in 58 consecutive patients with systemic lupus erythematosus. On 85 occasions serum IgG and IgM anticardiolipin antibodies were measured by an enzyme linked immunosorbent assay (ELISA), and simultaneous plasma samples tested for lupus anticoagulant activity. The most significant association with clinical events (previous thrombosis or thrombocytopenia occurring in 11/58 patients) was with prolonged tissue thromboplastin inhibition time (TTIT) followed by prolonged kaolin cephalin clotting time (KCCT) then raised IgG anticardiolipin antibody concentrations and dilute Russell's viper venom time. Although IgG anticardiolipin antibodies or KCCT were the most sensitive tests in identifying this group, the TTIT was the most specific (98%). Nine patients were IgG anticardiolipin antibody positive and lupus anticoagulant negative, of whom one had thrombocytopenia but none had thrombosis. The presence of a lupus anticoagulant in anticardiolipin antibody positive patients increases specificity for certain adverse clinical events.

AB - The significance of anticardiolipin antibodies and the lupus anticoagulant was studied in 58 consecutive patients with systemic lupus erythematosus. On 85 occasions serum IgG and IgM anticardiolipin antibodies were measured by an enzyme linked immunosorbent assay (ELISA), and simultaneous plasma samples tested for lupus anticoagulant activity. The most significant association with clinical events (previous thrombosis or thrombocytopenia occurring in 11/58 patients) was with prolonged tissue thromboplastin inhibition time (TTIT) followed by prolonged kaolin cephalin clotting time (KCCT) then raised IgG anticardiolipin antibody concentrations and dilute Russell's viper venom time. Although IgG anticardiolipin antibodies or KCCT were the most sensitive tests in identifying this group, the TTIT was the most specific (98%). Nine patients were IgG anticardiolipin antibody positive and lupus anticoagulant negative, of whom one had thrombocytopenia but none had thrombosis. The presence of a lupus anticoagulant in anticardiolipin antibody positive patients increases specificity for certain adverse clinical events.

M3 - Article

VL - 50

SP - 548

EP - 552

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 8

ER -